We're getting the new week started off right.

StockWireNews

Triggered Technicals And A Low Float Could Be Two Big (NMTC) Potential Catalysts (Nasdaq Past Champ)

March 7th

Greetings Readers,

We're getting the new week started off right.

Over the weekend, I put in some time researching a 2X Nasdaq past champ after doing a deep-dive when looking at its technicals.

But more on that in a sec...

On two previous occasions, I've delivered this breakout idea only to watch it catch fire short term.

In total, this profile was able to accumulate approximately 188% combined within a span of a few weeks each time.

And each time, this profile popped approximately $1.00+ on the way to donning the champ's crown.

Not shabby, but here's why you need to focus in again right now...

Going into Tuesday's opening bell, this profile has at least 10 triggered technical indicators according to Barchart, a low float of fewer than 14Mn shares, and a huge business update providing a spotlight of upcoming milestones.

That's only part of the reason why this Nasdaq 2X past champ needs immediate attention:

*NeuroOne Medical Technologies Corporation (NMTC)*

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs.

And right now, NMTC has 5 potential catalysts to immerse yourself in:

No. 1 - A Low Float Provides Volatility Potential Daily

No. 2 - Bullish Technical Indicators Are Appearing Across The Short, Medium, And Long Term

No. 3 - Business Update + Upcoming Targeted Milestones

No. 4 - Shipping/Order Of Evo sEEG System Seen As A "Monumental Achievement"

No. 5 - FDA 510(k) Clearance Is Most Exciting And Important Accomplishment To Date

But more on those in a second...

Brain Monitoring - Understanding What Allows Us To Sense, Move, Think And Feel. (1)

Neurons

86 BILLION NEURONS

Neurons communicate through electrical and chemical signals. The specific properties of the neurons composing a brain area and their connections with neurons in other brain areas, define the function of a brain area (e.g. language, vision, movement).

Monitoring Neural Activity

THEY CAN RECORD ELECTRICAL SIGNALS

There are different ways to record and monitor neural activity. Their solution is to provide electrodes that are placed on top of or within the brain and capture the activity of a group of neurons located underneath/around each contact. The signals recorded are called intracranial electroencephalogram (iEEG) or electrocorticography (ECoG) signals. The shape, amplitude and frequency of these electrical signals provide a readout of the activity of that brain area.

Monitoring Neurological Disorders

Neurological diseases may be associated with disturbances in neural activity and connectivity between brain areas. The changes in the shape, amplitude and frequency of recorded electrical signals may be used to identify areas with altered activity.

Epilepsy

Epilepsy is the disease associated with spontaneously recurring seizures. A seizure is a sudden, uncontrolled electrical disturbance in the brain. It can cause changes in behavior, movements or feelings, and in levels of consciousness. There are different types of seizures and their characterization and classification helps guide the treatment.

There are more than twenty seven FDA-approved drugs for the treatment of seizures. However, in ~1/3 of the patient's medication fails to control their seizures. These patients are candidates for surgical options.

Evo® Cortical Electrode

Cortical or subdural electrodes are used in electrocorticography (ECoG) or intracranial electroencephalography (iEEG) surgeries to monitor, record and stimulate the surface of the brain for up to 30 days. The company's Evo cortical electrode portfolio consists of various contact configurations of strip and grid electrodes. (Rx only)

image

The Evo Advantage (2)

Decreased Immunological Response - The Evo Electrode is over 7 times thinner than a silicone electrode. The flexibility and reduced volume should reduce pain and edema.

The Evo’s polyimide substrate has properties like increased flexibility, reduced volume, and decreased immunological response, which should reduce signal artifacts.

Single Tail Design - The single thin tail design allows the implanted electrode tail to be tunneled through one incision which should reduce infection risk and procedure time.

Reduced Cable Management - A disposable cable assembly is sent with each Evo Electrode as an electrode kit, removing the need to source the correct cables for each electrode being used in surgery. Also, hospital resources are freed from the management of sterilizing and storing individual electrode cable assemblies.

image

How NeuroOne's Thin Film Electrode Technology is Different

In comparison to currently available technologies, our electrodes are manufactured with polyimide thin film. Our electrodes are designed to reduce trauma to the brain by allowing a less invasive implant due to the flexibility, thinness and reduced weight of the electrode.

Furthermore, the potential to significantly increase the resolution of brain recordings may enable the usage of powerful computing techniques, such as machine learning and artificial intelligence.

Caution: US Federal law restricts this device to sell by or on the order of a physician

Two FDA-Cleared Devices and Counting (3)

Are you beginning to understand that NeuroOne is not just “another” MedTech company? In fact, their Evo Cortical and sEEG Electrodes are both FDA approved!

What they are doing right now has incredible implications for the future of the medical industry.

So much so that the technologies below could be commonplace and in wide use across the globe.

image

Read more from the company presentation here.

-----

And as I mentioned previously, NMTC has 5 must-see potential catalysts right now:

No. 1 NMTC Potential Catalyst - A Low Float Provides Volatility Potential Daily

According to the Yahoo Finance website, NMTC has a low float.

The website reports this profile to have approximately 13.71Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could positive 2023 company news help provide a near term spark?

-----

No. 2 NMTC Potential Catalyst - Bullish Technical Indicators Are Appearing Across The Short, Medium, And Long Term

I'm telling you right now... Don't discount NMTC's technical indicators.

At 11:00AM EST Monday, NMTC was displaying several triggered technical indicators across the short, medium term, and long term.

Barchart was reporting these technical indicators as triggered:

Short Term Indicators

  • 20 - 50 Day MACD Oscillator
  • 20 - 100 Day MACD Oscillator
  • 20 - 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 - 150 Day MACD Oscillator
  • 50 - 200 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average
  • 100 - 200 Day MACD Oscillator

The website also shares its all-important "Trend Seeker" composite indicator is triggered, too.

Could this be a signal that NMTC could be gearing up for a special move ahead?

-----

No. 3 NMTC Potential Catalyst - Business Update + Upcoming Targeted Milestones

NeuroOne® Reports First Quarter Fiscal Year 2023 Fi-nan-cial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Feb. 14, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal first quarter 2023 ended December 31, 2022.

Fiscal First Quarter 2023 and Recent Business Updates

  • Received FDA 510(k) clearance to market the Evo® sEEG Electrode technology for temporary (less than 30 day) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, enabling NeuroOne to fully address the approximately $100M diagnostic electrode market.
  • A feasibility animal study of the Company's OneRF® therapeutic radiofrequency ablation electrode system was completed under the guidance of Dr. Jamie Van Gompel at the Mayo Clinic in Rochester, MN. OneRF is an sEEG probe-guided RF based system to monitor and adjust settings based on temperature throughout an ablation, a feature designed to improve the safety of the procedure.
  • The first commercial order of Evo® sEEG electrodes for temporary use (less than 30 days) was shipped to the Company's distribution and development partner Zimmer Biomet. NeuroOne continues to build up inventory to meet product forecasts and fulfill additional orders in-house.
  • The Company developed and successfully bench tested an early prototype of a first-of-a-kind device that can deliver drugs (or other diagnostic or therapeutic agents) to the brain while also having the capability to stimulate and record before and after application.
  • Held discussions with strategic organizations regarding the Company's technology in an effort to potentially expand the product footprint in neurology.
  • Exhibited the Evo electrode product family with Zimmer Biomet at the Congress of Neurological Surgeons annual meeting and the American Epilepsy Society and Congress of Neurological Surgeons annual meetings.

...

  • CEO Dave Rosa featured on Fox Business Network's 'Mornings with Maria.'
  • Rang Nasdaq St-ock Market closing bell to commemorate the FDA clearance milestone for Evo sEEG Electrode technology.

Dave Rosa, CEO of NeuroOne, commented, "We were thrilled to receive FDA clearance of our Evo sEEG electrode, which was the culmination of years of hard work and determination. This represents the beginning of our commercialization strategy with Zimmer Biomet. Just as critical, we are well positioned to submit our OneRF Ablation System to the FDA for 510(k) clearance, marking a key milestone for the Company as we enter the therapeutic space. We continue to explore additional exciting markets as we seek to improve upon existing technology with the goal of making current procedures safer and more cost effective, with potential improved efficacy for patients suffering from epilepsy, Parkinson's disease, and chronic pain. We also continue to explore potential strategic partnerships to expand our presence beyond our current areas of focus."

Upcoming Targeted Milestones

  • Commercial launch of Evo sEEG electrodes with Zimmer Biomet in the first quarter of calendar year 2023.
  • Along with Zimmer Biomet, present the newly launched Evo sEEG system at the American Association of Neurological Surgeons (AANS) annual meeting at the end of April 2023.
  • Submit a 510(k) application to the FDA for OneRF in the second quarter of calendar year 2023.
  • Complete design verification testing for OneRF confirming that the full feature system meets its design specifications and is fully functional.
  • Complete next in vivo animal testing of the OneRF system with multiple surgeons with the objective of gathering additional in vivo data on the system's performance.
  • Pre-clinical implantation for spinal cord stimulation (SCS) electrodes intended for permanent implant to treat chronic pain.

...

Read the full article here.

-----

No. 4 NMTC Potential Catalyst - Shipping/Order Of Evo sEEG System Seen As A "Monumental Achievement"

NeuroOne® Ships Initial Zimmer Biomet Order for its Evo® sEEG System for Less than 30 Day Use

Company focused on manufacturing and commercialization in partnership with Zimmer Biomet

EDEN PRAIRIE, Minn., Nov. 30, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it shipped the first commercial order to Zimmer Biomet for its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. Zimmer Biomet is the exclusive worldwide distribution partner for the NeuroOne Evo Cortical and sEEG electrode product lines.

"This shipment represents a monumental accomplishment for the Company. Without the persistence of our staff and manufacturing partners, we could not have reached this point. We look forward to commercialization of this exciting technology in the future in partnership with Zimmer Biomet," said Dave Rosa, CEO of NeuroOne.

The Evo sEEG System represents the Company's second FDA 510(k) cleared product. NeuroOne now provides a full line of electrode technology to address an estimated worldwide market of $100Mn for patients requiring diagnostic brain mapping procedures. As opposed to cortical electrodes, sEEG electrodes provide a similar function at the subsurface level of the brain by using a much less invasive process that does not require removal of the top portion of the patient's skull. sEEG electrodes are the predominant technology used in these procedures due to their less invasive placement and subsurface location.

...

As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation and chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. These therapeutic electrode technologies represent addressable markets valued between $500Mn and $6Bn.

Read the full article here.

-----

No. 5 NMTC Potential Catalyst - FDA 510(k) Clearance Is Most Exciting And Important Accomplishment To Date

NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use

Company focused on manufacturing ramp for commercialization in partnership with Zimmer Biomet

EDEN PRAIRIE, Minn., Oct. 25, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

...

"I am extremely proud of the entire NeuroOne team and their relentless pursuit of this clearance. Despite the challenges we faced, our team remained focused and persistent in driving this successful conclusion. This is clearly our most exciting and important accomplishment to date. We are now able to advance our commercialization efforts in partnership with Zimmer Biomet, our distribution and development partner. We look forward to continuing to execute our strategic plan, which next up includes our RF ablation system, the Company's first therapeutic electrode technology," said Dave Rosa, CEO of NeuroOne.

The Evo sEEG System represents the Company's second FDA 510(k) cleared product. NeuroOne now provides a full line of electrode technology to address an estimated worldwide market of $100Mn for patients requiring diagnostic brain mapping procedures. As opposed to cortical electrodes, sEEG electrodes provide a similar function at the subsurface level of the brain by using a much less invasive process that does not require removal of the top portion of the patient's skull. sEEG electrodes are the predominant technology used in these procedures due to their less invasive placement and subsurface location.

The Company's Evo Cortical and sEEG Electrodes are a portfolio of hi-definition thin film electrodes. Potential advantages include increased signal clarity and reduced noise; better tactile feedback during insertion into brain tissue; and faster order fulfillment due to an automated manufacturing process.

As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation and chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. These therapeutic electrode technologies represent addressable markets valued between $500Mn and $6Bn.

Read the full article here.

-----

NMTC Recap: 5 Potential Breakout Catalysts To Know Immediately

No. 1 - A Low Float Provides Volatility Potential Daily

No. 2 - Bullish Technical Indicators Are Appearing Across The Short, Medium, And Long Term

No. 3 - Business Update + Upcoming Targeted Milestones

No. 4 - Shipping/Order Of Evo sEEG System Seen As A "Monumental Achievement"

No. 5 - FDA 510(k) Clearance Is Most Exciting And Important Accomplishment To Date

-----

Coverage is officially reinitiated on NMTC. When time permits, do this:

image

Get NMTC on your radar now.

Sincerely,

Kai Parker

StockWireNews


Source 1
Source 2
Source 3


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 8/7/22 and ending on 8/9/22 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 11/20/22 and ending on 11/21/22 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 3/6/23 and ending on 3/7/23 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid two thousand five hundred USD via bank wire transfer. We own zero shares of (NMTC). To date we have been compensated a total of forty-seven thousand USD via bank wire transfer to disseminate information about (NMTC). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 03/07/2023 and ending on 03/08/2023 to publicly disseminate information about (NMTC:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid two hundred twenty thousand dollars USD to disseminate information about (NMTC:US) via digital communications. We own zero shares of (NMTC:US). lifewatermedia.com/nmtc-disclosure-33/